Pfizer said it's developing a once-daily GLP-1 weight loss pill. In postmenopausal women with osteoporosis, romosozumab ...

Pfizer announced that it has selected its preferred once-daily modified release formulation of danuglipron, a move that is ...

Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, ...

Pfizer announced Thursday plans to move forward with an oral daily weight loss medication in the same drug category as ...

Pfizer Inc. announced on Thursday that it will move forward with the testing of its modified version of the once-daily weight ...

(Reuters) -Pfizer plans to move a reworked, once-a-day version of its weight loss pill, danuglipron, into clinical trials ...

One of the most notorious insider trading schemes in U.S. history has led to a $75 million fight between drugmaker Pfizer and ...

Pfizer inadvertently gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release ...

Pfizer said it saw “encouraging” data from an ongoing early stage trial of its oral weight loss drug, danuglipron.

Investors with a lot of money to spend have taken a bullish stance on Pfizer PFE. And retail traders should know. We noticed ...

Pfizer has dragged the oral GLP-1 candidate danuglipron back from the brink. Months after dropping one version of the asset, ...

Pharmaceutical giant Pfizer’s (NYSE:PFE) stock is down over 14% in the past year. At the same time, rivals Eli Lilly ...